Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Stopped Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.

Conditions

• Duchenne Muscular Dystrophy

Interventions

• DRUG: BMN 044 IV 6 mg/kg
• DRUG: BMN 044 IV 9 mg/kg
• DRUG: BMN 044 SC 6 mg/kg

Sponsor

BioMarin Pharmaceutical